Log in

NASDAQ:LNTH - Lantheus Stock Price, Forecast & News

$12.12
-0.49 (-3.89 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$12.01
Now: $12.12
$12.63
50-Day Range
$9.11
MA: $14.68
$17.69
52-Week Range
$8.67
Now: $12.12
$29.80
Volume362,769 shs
Average Volume590,121 shs
Market Capitalization$481.41 million
P/E Ratio15.34
Dividend YieldN/A
Beta1.46
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures to assess blood flow to the muscle of the heart; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical used in the manufacture of sources for the calibration and maintenance of single-photon emission computed tomography imaging cameras. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment follow-up of neuroendocrine tumors. The company sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Read More
Lantheus logo

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LNTH
CUSIPN/A
Phone978-671-8001

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$347.34 million
Cash Flow$1.50 per share
Book Value$2.92 per share

Profitability

Net Income$31.67 million

Miscellaneous

Employees488
Market Cap$481.41 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive LNTH News and Ratings via Email

Sign-up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.


Lantheus (NASDAQ:LNTH) Frequently Asked Questions

How has Lantheus' stock been impacted by COVID-19 (Coronavirus)?

Lantheus' stock was trading at $13.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LNTH stock has decreased by 11.0% and is now trading at $12.12. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Lantheus?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Lantheus.

When is Lantheus' next earnings date?

Lantheus is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Lantheus.

How were Lantheus' earnings last quarter?

Lantheus Holdings Inc (NASDAQ:LNTH) released its earnings results on Tuesday, February, 25th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.30 by $0.04. The medical equipment provider earned $89.35 million during the quarter, compared to analyst estimates of $90.62 million. Lantheus had a net margin of 9.12% and a return on equity of 45.81%. Lantheus's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.29 EPS. View Lantheus' earnings history.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus updated its FY20 earnings guidance on Tuesday, February, 25th. The company provided earnings per share (EPS) guidance of $1.34 to $1.40 for the period, compared to the Thomson Reuters consensus estimate of $1.03. The company issued revenue guidance of $384 million to $390 million, compared to the consensus revenue estimate of $382.92 million.

Has Lantheus been receiving favorable news coverage?

Media coverage about LNTH stock has been trending extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Lantheus earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View the latest news aboutLantheus.

Are investors shorting Lantheus?

Lantheus saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,518,600 shares, an increase of 51.7% from the February 27th total of 1,660,000 shares. Based on an average trading volume of 542,300 shares, the days-to-cover ratio is currently 4.6 days. Currently, 6.9% of the company's shares are short sold. View Lantheus' Current Options Chain.

Who are some of Lantheus' key competitors?

What other stocks do shareholders of Lantheus own?

Who are Lantheus' key executives?

Lantheus' management team includes the following people:
  • Ms. Mary Anne Heino, CEO, Pres & Director (Age 59)
  • Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 52)
  • Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 58)
  • Dr. Cesare Orlandi, Chief Medical Officer (Age 69)
  • Mr. John J. Bolla, Chief Operating Officer (Age 49)

When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (3.76%), Renaissance Technologies LLC (3.58%), Vaughan Nelson Investment Management L.P. (3.38%), LSV Asset Management (3.25%), Nuveen Asset Management LLC (1.86%) and Tamarack Advisers LP (1.66%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View institutional ownership trends for Lantheus.

Which institutional investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Rice Hall James & Associates LLC, Renaissance Technologies LLC, Royce & Associates LP, Citigroup Inc., Tamarack Advisers LP, Alliancebernstein L.P., and AQR Capital Management LLC. Company insiders that have sold Lantheus company stock in the last year include Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno, and Tudor Brown. View insider buying and selling activity for Lantheus.

Which institutional investors are buying Lantheus stock?

LNTH stock was bought by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Russell Investments Group Ltd., Bank of Montreal Can, Prudential Financial Inc., Public Sector Pension Investment Board, Geode Capital Management LLC, First Trust Advisors LP, and Great West Life Assurance Co. Can. View insider buying and selling activity for Lantheus.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $12.12.

How big of a company is Lantheus?

Lantheus has a market capitalization of $481.41 million and generates $347.34 million in revenue each year. The medical equipment provider earns $31.67 million in net income (profit) each year or $1.17 on an earnings per share basis. Lantheus employs 488 workers across the globe. View additional information about Lantheus.

What is Lantheus' official website?

The official website for Lantheus is http://www.lantheus.com/.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]


MarketBeat Community Rating for Lantheus (NASDAQ LNTH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  279 (Vote Outperform)
Underperform Votes:  267 (Vote Underperform)
Total Votes:  546
MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel